Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $1.93 Average Target Price from Brokerages
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. […]